摘要
目的 探讨血清CEA、CA19 9、CA72 4的检测对大肠癌诊断的临床应用价值。方法 采用ELISA方法对 89例大肠癌患者进行了分析。结果 DukesC +D期患者CEA、CA19 9、CA72 4阳性率明显高于DukesA +B期患者(分别为 6 4 %vs 2 6 %、4 6 %vs2 2 %、2 6 %vs8% ,P <0 0 5 ) ,其值大小明显高于DukesA +B期患者 (分别为 12 5 9± 30 6 9ng/mlvs 12 7± 4 4 4ng/ml、12 5 1 9± 4 0 5 8 2U/mlvs 12 4 3±6 32 5U/ml、14 0± 32 1U/mlvs3 4± 4 1U/ml,P <0 0 5 ) ,与肿瘤分化无关 ,CEA、CA19 9、CA72 4联合检测阳性率为 6 1% ,明显高于各单项检测的阳性率 (分别为 4 3%、33%、16 % ,P <0 0 1)。结论 CEA、CA19 9、CA72 4可用于大肠癌的诊断、病情判断 ,联合检测可提高诊断效率。
Objective To investigate the clinical value of serum CEA, CA19-9 and CA724 in patients with colonic carcinoma. Methods Serum levels of CEA, CA19-9 and CA724 were detected with ELISA in 89 patients suffering from colonic cancer. Results The positive rates of CEA, CA19-9 and CA724 in Dukes' stages C and D patients were remarkably higher than those in Dukes' stages A and B patients(64% vs 26%,46% vs 22%,26% vs 8% respectively, P<0.05)with no relation to tumor differentiation. The values of CEA,CA19-9 and CA724 were also higher [(125.9±306.9)ng/ml vs (12.7±44.4)ng/ml, (1 251.9±4 058.2)U/ml vs (124.3±632.5)U/ml,(14.0±32.1)U/ml vs (3.4±4.1)U/ml respectively, P<0.05] in the former than the latter. The positive rate of CEA, CA19-9 and CA724 in combination was 61%, which was significantly higher than that of single marker(43%, 33%, 16% respectively, P<0.01). Conclusion The results suggest that determination of CEA, CA19-9 and CA724 are valuable for the diagnosis of colonic carcinoma and evaluation of patient's conditions, and diagnostic value can be enhanced by determination of CEA, CA19-9 and CA724 in combination.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2004年第1期69-70,共2页
Medical Journal of Chinese People's Liberation Army
